ArticleCancer research2020
IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors.
Open access · bronzeAbstract readComment
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Rheumatoid arthritis reduces the risk of colorectal cancer through immune inflammation mediation.Journal of cellular and molecular medicine · 2024Pooled it
- Impact of IL-6 receptor inhibitors on cerebrospinal fluid metabolites in type 2 diabetes patients.Medicine · 2026Article
- Contextualizing TNature reviews. Immunology · 2026Review
- In vivo CAR-T therapy: from molecular design to precision delivery.Journal of nanobiotechnology · 2026Review
- Interleukin-6: The Unexpected Opponent to Pancreatic Cancer.Cellular and molecular gastroenterology and hepatology · 2026Article
- Mechanisms of T cell-mediated antitumor immunity within tertiary lymphoid structures.Frontiers in immunology · 2026Review
- Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity.Cancer cell · 2025Article
- Constructing the cure: engineering the next wave of antibody and cellular immune therapies.Journal for immunotherapy of cancer · 2025Review
- Review
- Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2024Review
- Review
- Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.Journal for immunotherapy of cancer · 2024Article
- Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy.Frontiers in immunology · 2024Article
- STING-driven activation of T cells: relevance for the adoptive cell therapy of cancer.Cell stress · 2023Review
- The application of machine learning methods to the prediction of novel ligands for RORComputational and structural biotechnology journal · 2023Article
- Factors impacting the benefits and pathogenicity of Th17 cells in the tumor microenvironment.Frontiers in immunology · 2023Review
- The protective and pathogenic role of Th17 cell plasticity and function in the tumor microenvironment.Frontiers in immunology · 2023Review
- OXPHOS promotes apoptotic resistance and cellular persistence in TScience immunology · 2022Article
- Chemopreventive Effect on Human Colon Adenocarcinoma Cells of Styrylquinolines: Synthesis, Cytotoxicity, Proapoptotic Effect and Molecular Docking Analysis.Molecules (Basel, Switzerland) · 2022Article
- Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition.Frontiers in oncology · 2022Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
14 authors at 3 institutions in 1 country.
Hannah M KnochelmannDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina. knochelm@musc.edu chrystal.mary.paulos@emory.edu.
Connor J DwyerDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.
Aubrey S SmithDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-3693-4262
Jacob S BowersDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-2589-2351
Megan M WyattDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.
Michelle H NelsonDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0001-7597-0923
Guillermo O Rangel RiveraDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.
Joshua D HortonDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.
Carsten KriegDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-5145-7591
Kent ArmesonDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.
Gregory B LesinskiDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Mark P RubinsteinDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.
Zihai LiPelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio.ORCID 0000-0003-4603-927X
Chrystal M PaulosDepartment of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina. knochelm@musc.edu chrystal.mary.paulos@emory.edu.
Medical University of South Carolina · USEmory University · USThe Ohio State University · US
Funding
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7MT-COHR: Training in Craniofacial and Oral Health ResearchT32DE017551 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YAO, HAI · 2006 to 2025
$10.3MTRAINING PROGRAM FOR MEDICAL SCIENTISTST32GM008716 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DEMORE, NANCY · 1999 to 2024
$9.3MProteomics CoreP30DK123704 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DON C. ROCKEY · 2020 to 2026
$8.8MProject 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI GEWIRTH, DANIEL T · 2015 to 2019
$6.7MMolecular chaperones and immune toleranceR01AI077283 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LI, ZIHAI · 2009 to 2021
$3.7MLymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responsesR01CA222817 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RUBINSTEIN, MARK P, WRANGLE, JOHN M. · 2019 to 2023
$2.0MMechanisms of durable antitumor immunity via CD26hiCD4+ T cellsR01CA208514 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2016 to 2020
$1.7MCostimulatory mechanisms of antitumor Th17 cell immunityR01CA175061 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2013 to 2017
$1.5MProgram in Immunology Research and Entrepreneurship (PIRE)T32AI132164 · NIAID · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TOMLINSON, STEPHEN · 2017 to 2021
$1.2MResearch Specialist Support of a Well-Established Cancer Immunotherapy Research Program Focused on Improving Adoptive T Cell Therapy (ACT)R50CA233168 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WYATT, MEGAN M · 2018 to 2022
$532kThe role of DCLK1 in the initiation of pancreatic ductal adenocarcinoma and colorectal cancerR50CA233186 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI QU, DONGFENG · 2018 to 2022
$448kNCI NIH HHS F30 CA200272NCI NIH HHS F30 CA243307NCI NIH HHS P01 CA186866NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA175061NCI NIH HHS R01 CA208514NCI NIH HHS R01 CA222817NCI NIH HHS R50 CA233168NCI NIH HHS R50 CA233186NIAID NIH HHS R01 AI077283NIAID NIH HHS T32 AI132164NIDCR NIH HHS T32 DE017551NIDDK NIH HHS P30 DK123704NIGMS NIH HHS T32 GM008716
Abstract
The accessibility of adoptive T-cell transfer therapies (ACT) is hindered by the cost and time required for product development. Here we describe a streamlined ACT protocol using Th17 cells expanded only 4 days
Indexed as
NeoplasmsTh17 CellsCell- and Tissue-Based TherapyCytokinesHumansInterleukin-6CytokinesInterleukin-6
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.